The uptake of ciclesonide-active metabolite and budesonide into human hepatocytes in vitro – the effect of serum protein binding Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Different tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006
Corticosteroid lipophilicity is a more important determinant of corticosteroid uptake into human hepatocytes than serum protein binding Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Pulmonary targeting of ciclesonide and its active metabolite as determined in an ex-vivo rat receptor-binding assay Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
Unbound pharmacologically active metabolite des-CIC is not detectable in human skeletal muscle and subcutaneous adipose tissue after inhalation of high-dose ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Exposure of human subcutaneous adipose tissue and skeletal muscle tissue to unbound active drug after inhalation of high-dose ciclesonide or budesonide Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Synergistic action of formoterol on budesonide-generated decrease of proteoglycan production by activated lung fibroblasts is mediated via β-adrenergic receptor and is dependent on glucocorticoid receptor Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Deposition and metabolism of inhaled ciclesonide in the human lung Source: Eur Respir J 2010; 36: 1113-1119 Year: 2010
In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cellsSource: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Glycosaminoglycan synthesis is modulated by ciclesonide in human lung cells Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Topically applied budesonide and formoterol in combination inhibit rat lung oedema in a synergistic way but counteract the slight systemic effects of each drug alone on body weight gain Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Pharmacokinetic factors affecting airway selectivity of inhaled steroids – role of prodrug conversion and absorption Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004
‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
Tissue retention and esterification is greater for budesonide than for ciclesonide in trachea ex vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Anti-inflammatory efficacy of formoterol via transrepressive mechanisms is independent of the glucocorticoid receptor in human bronchial epithelial cells Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
HDAC2-independent anti-inflammatory effects of budesonide in human lung fibroblasts Source: Annual Congress 2011 - Recent developments in COPD Year: 2011
Pharmacokinetic factors affecting airway selectivity of inhaled steroids - role of intracellular esterification Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001